Lora Rabin Dagi Glass, MD

Brian Marr, MD heads the Ophthalmic Oncology Service at the Harkness Eye Institute. He has comprehensive experience in the diagnosis, treatment, and management of ocular tumors including intraocular tumor resection, laser, radiation, and chemotherapy procedures. He has helped devise thousands of complex treatments for tumors of the eye, eyelid, orbit, and conjunctiva for his adult, children, and infant patients. Currently, Dr. Marr is a collaborator on a Columbia University clinical trial for a first-of-its-kind, new class of drug treatment for uveal melanoma. Dr. Marr is a board-certified ophthalmologist whose work has centered around ophthalmic oncology since 2000. One of the very few ocular oncologists trained in all aspects of eye cancer, Dr. Marr's clinical experience in treating these diseases is among the most extensive in the United States. His interest and experience in ophthalmic oncology began during an eight-year tenure in the Ocular Oncology Service at the Wills Eye Hospital in Philadelphia. There, he gained extensive experience treating intraocular tumors, and tumors of the eyelid, orbit, and conjunctiva in children and adults. It was there that Dr. Marr developed and improved many surgical procedures used to cure cancers of the eye, successfully treated thousands of patients, and helped their families though their battle with eye cancer. Next, Dr. Marr moved on to Memorial Sloan Kettering Cancer Center, where he remain for nine years, starting in 2008. Dr. Marr has some of the greatest experience with intra-arterial chemotherapy for treating retinoblastoma in the country, if not the world, as well as all other forms of retinoblastoma treatment. He has been a key member of many multidisciplinary surgical teams, treating advanced skull base tumors and complex facial skin lesions. He has developed a strong belief and treatment philosophy that the best research be used to help his patients, rather than his best patients be used to help his research. The field of ophthalmic oncology encompasses many rare conditions and his experience helps his patients get the best care and results as quickly as possible. Dr. Marr lectures and consults across the US and abroad, and has authored numerous research articles in the field of ocular oncology. He is the principal investigator in a first-in-class drug study for treating primary uveal melanoma, in an international, multi-center trial. He also volunteers his medical expertise in underserviced parts of the world, such as Nigeria and Indonesia, and has helped train physicians in more than 20 countries. Dr. Marr’s efforts as a contributor to ongoing education in ocular oncology have been recognized by the American Academy of Ophthalmology, where he now serves as chief editor of the Academy’s Oncology and Pathology’s One network.

Scott E. Brodie, MD, Ph.D., is a Professor of Clinical Ophthalmology and Attending Ophthalmologist in the Department of Ophthalmology. He is an internationally known clinician-scientist, and a leader in the use of electrophysiologic techniques for diagnosing of visual impairments in children and adults.Dr. Brodie is a graduate of the combined MD-PhD program at Weill-Cornell Medical College and The Rockefeller University in New York. He completed his PhD in retinal physiology in the laboratory of Nobel Laureate H. K. Hartline, under the supervision of Dr. Floyd Ratliff and Prof. Bruce Knight. He completed a medical internship and residency training in ophthalmology at The New York Hospital, and subsequently received fellowship training in medical retinal disorders and clinical electrophysiology of vision at New York University and Bellevue Hospital under the supervision of Dr. Ronald Carr, with support as a John Kluge Fellow of the Retinitis Pigmentosa Foundation.He is a fellow of the American Academy of Ophthalmology, and a fellow of the Association for Research in Vision and Ophthalmology. He is a member of the International Society for Clinical Electrophysiology of Vision, the International Society for Genetic Eye Disease, and the Ophthalmic Genetics Study Club. Dr. Brodie has been honored with the Senior Achievement Award of the American Academy of Ophthalmology, as well as the Academy's Secretariat Award for Education.Dr. Brodie’s research centers on improving methodologies for electrophysiologic testing, and descriptions of novel findings in patients with inherited and metabolic retinal disorders. He has been a key member of the teams which have introduced important new therapies, including enzyme-replacement therapy for Fabry disease, and intra-arterial chemotherapy for retinoblastoma, which has increased the rate of salvage of diseased eyes in the most severely affected patients from 20% to over 90%.Dr. Brodie has published extensively on electrophysiology and retinal disorders. He has a particular interest in clinical optics, and has served as Chair of the Editorial committee for the American Academy of Ophthalmology’s Basic and Clinical Science Course on Clinical Optics for the past ten years. In his spare time, he enjoys reading mathematics, and playing the oboe in local orchestras and chamber groups.

Daniel Diamond, OD, is Assistant Professor of Optometric Sciences (in Ophthalmology) at Columbia University Irving Medical Center. Dr. Diamond specializes in pediatrics, anterior segment disease, contact lens fitting, and primary and post-operative care. Dr. Diamond received his bachelor's degree in biology with a concentration in Molecular Biology at SUNY Binghamton. He then went on to complete his Doctorate in Optometry at the New England College of Optometry. He obtained his residency training in ocular disease at ENRM VA Hospital in Bedford, MA. Since joining the department, Dr. Diamond has received a fellowship from the American Academy of Optometry, published work on the vision and eye health of at-risk individuals in New York City, and lectured on the use of contact lenses in infants.